Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-09-27
2005-09-27
Romeo, David S. (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S005000, C435S320100, C435S475000, C530S324000, C530S350000
Reexamination Certificate
active
06949349
ABSTRACT:
Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
REFERENCES:
patent: 4411890 (1983-10-01), Momany
patent: 4876242 (1989-10-01), Applebaum et al.
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5068224 (1991-11-01), Fryklund et al.
patent: 5077276 (1991-12-01), Ballard et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5106832 (1992-04-01), Froesch et al.
patent: 5126324 (1992-06-01), Clark et al.
patent: 5164370 (1992-11-01), Ballard et al.
patent: 5187151 (1993-02-01), Clark et al.
patent: 5202119 (1993-04-01), Clark et al.
patent: 5206235 (1993-04-01), Fisher et al.
patent: 5210017 (1993-05-01), Carlsson et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5273961 (1993-12-01), Clark
patent: 5374620 (1994-12-01), Clark et al.
patent: 5466670 (1995-11-01), Dunger et al.
patent: 5470828 (1995-11-01), Ballard et al.
patent: 5534617 (1996-07-01), Cunningham et al.
patent: 5569648 (1996-10-01), Lewis et al.
patent: 5593844 (1997-01-01), Carlsson et al.
patent: 5597797 (1997-01-01), Clark
patent: 5622932 (1997-04-01), DiMarchi et al.
patent: 5652214 (1997-07-01), Lewis et al.
patent: 5703045 (1997-12-01), Lewis et al.
patent: 5714460 (1998-02-01), Gluckman et al.
patent: 5776897 (1998-07-01), Lewis et al.
patent: 128733 (1984-12-01), None
patent: 135094 (1985-03-01), None
patent: 230869 (1987-08-01), None
patent: 288451 (1988-10-01), None
patent: 294021 (1988-12-01), None
patent: 369943 (1990-05-01), None
patent: 375438 (1990-06-01), None
patent: 379338 (1990-07-01), None
patent: 681842 (1995-11-01), None
patent: 742228 (1996-11-01), None
patent: 965596 (1999-12-01), None
patent: WO 89/05822 (1989-06-01), None
patent: WO 89/08667 (1989-09-01), None
patent: WO 89/09268 (1989-10-01), None
patent: WO 89/09792 (1989-10-01), None
patent: WO 91/03253 (1991-03-01), None
patent: WO 92/11865 (1992-07-01), None
patent: WO 92/15679 (1992-09-01), None
patent: WO 93/08826 (1993-05-01), None
patent: WO 93/20836 (1993-10-01), None
patent: WO 93/23071 (1993-11-01), None
patent: WO 93/25219 (1993-12-01), None
patent: WO 94/04569 (1994-03-01), None
patent: WO 94/16722 (1994-08-01), None
patent: WO 94/16723 (1994-08-01), None
patent: WO 95/07697 (1995-03-01), None
patent: WO 95/17422 (1995-06-01), None
patent: WO 95/17423 (1995-06-01), None
patent: WO 96/01124 (1996-01-01), None
patent: WO 96/15148 (1996-05-01), None
patent: WO 96/33216 (1996-10-01), None
patent: WO 96/37514 (1996-11-01), None
patent: WO 96/40189 (1996-12-01), None
patent: WO 96/40750 (1996-12-01), None
patent: WO 97/37010 (1997-10-01), None
patent: WO 97/39032 (1997-10-01), None
patent: WO 00/23469 (2000-04-01), None
Alberts et al.Moelcular Biology of the Cell, 3RD edition, New York:Garland Publishing, Inc. pps. 119 (1994).
Bach and Rechler, “Insulin-like Growth Factor Binding Proteins”Diabetes Reviews3:38-61 (1995).
Ballard et al., “Does IGF-I Ever Act Through the Insulin Receptor?”The Insulin-like Growth Factors and Their Regulatory Proteins, Baxter, eds., Amsterdam: Elsevier pps. 131-138 (1994).
Bar et al., “Tissue localization of perfused endothelial cell IGF binding protein is markedly altered by association with IGF-I”Endocrinology127(6):3243-3245 (1990).
Bass et al., “Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties”Proteins: Structure, Function, and Genetics8(4):309-314 (1990).
Baxter & Martin, “Binding Proteins for Insulin-Like Growth Factors in Adult Rat Serum. Comparison With Other Human and Rat Binding Proteins”Biochem.&Biophys. Res. Comm.147(1):408-415 (1987).
Baxter et al., “Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3”Journal of Biological Chemistry267(1):60-65 (Jan. 5, 1992).
Baxter, “Physiological Roles of IGF Binding Proteins”Modern Concepts of Insulin-like Growth Factors, Spencer, eds., Elsevier New York pps. 371-380 (1991).
Baxter, “The somatomedins: insulin-like growth factors”Advances in Clinical Chemistry25:49-115 (1986).
Baxter, R., “The Insulin-Like Growth Factors and Their Binding Proteins”Comp. Biochem. Physiol.91B(2):229-235 (1988).
Bayne et al., “Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor”Journal of Biological Chemistry263:6233-6239 (1988).
Bayne et al., “The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor”Journal of Biological Chemistry264 (19):11004-11008 (Jul. 5, 1989).
Bayne et al., “The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type I insulin-like growth factor receptor”Journal of Biolgoical Chemistry265(26):15648-15652 (Sep. 15, 1990).
Binkert et al., “Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)”EMBO Journal8:2497-2502 (1989).
Binoux, M., “Donnees recentes sur les somatomedines (Insulin-like growth factors)”Annales d'Endocrinologie41:157-192 (1980).
Bondy, C., “Clinical uses of insulin-like growth factor I”Annals of Internal Medicine120:593-601 (1994).
Bowers, C. Y., “GH Releasing Peptides—Structure and Kinetics”J. Pediatr. Endocrinology6(1):21-31 (1993).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”Science247:1306-1310 (1990).
Brandt et al., “Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide”American Journal of Physiology269(1 Pt 2) :H326-H331 (Jul. 1995).
Brewer et al., “Cloning, Characterization, and Expression of a Human Insulin-Like Growth Factor Binding Protein”Biochem.&Biophys. Res. Comm.152(3):1289-1297 (1988).
Brinkman et al., “Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)”The EMBO J.7:2417-2423 (1988).
Carlsson et al., “Growth Hormone and Growth in Diabetic Rats: Effects of Insulin and Insulin-Like Growth Factor-I Infusions”J. Endocrinol.122:661-670 (1989).
Cascieri et al., “Analysis of the interaction of IGF-I analogs with the IGF-I receptor and IGF binding proteins”Advances in Experimental Medicine&Biology343:33-40 (1993).
Cascieri et al., “Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor”Biochemistry27(9):3229-3233 (May 3, 1988).
Cascieri et al., “Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors”Journal of Biological Chemistry264:2199-2202 (1989).
Charlton et al., “Growth hormone-deficient dwarfism in the rat: a new mutation”J. of Endocrinology119:51-58 (1988).
Cheetham et al., “The Effects of Recombinant Human Insulin-like Growth Factor I on Growth Hormone Secretion in Adolescents With Insulin Dependent Diabetes Mellitus”Clin. Endocrinol.40:515-522 (1994).
Cheetham et al., “The Effects of Recombinant Insulin-like Growth Factor I Administration on Growth Hormone Levels and Insulin Requirements in Adolescents With Type 1 (Insulin-dependent) Diabetes Mellitus”Diabetologia36:678-681 (1993).
Chen et al., “Recombinant human IGF-I infusion results in transient improvement in nitrogen balance: evidence for IGF-I autoregulation”US Endocrine Meeting(Abstract 1596) pps. 449 (1993).
Clark et al., “Growth-Responses to Patterned GH Delivery”Endocrine3:717-723 (1995).
Clark et al., “Insulin-L
Clark Ross G.
Lowman Henry B.
Robinson Iain C. A. F.
Dreger, Esq. Ginger R.
Genentech Inc.
Hasak Janet E.
Heller Ehrman LLP
Romeo David S.
LandOfFree
Insulin-like growth factor agonist molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Insulin-like growth factor agonist molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin-like growth factor agonist molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3401613